Want to see FTH full AI Analyst Report?
FTH Stock Chart & Stats
$32.97
-$0.03(-5.03%)
At close: 4:00 PM EST
$32.97
-$0.03(-5.03%)
Day’s Range― - ―
52-Week Range$7.45 - $42.14
Previous CloseN/A
VolumeN/A
Average Volume (3M)299.22K
Market Cap
$913.98M
Enterprise Value-$38.00
Total Cash (Recent Filing)$186.44M
Total Debt (Recent Filing)$592.00K
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Nov 10, 2026EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-141.65
Shares Outstanding25,840,425
10 Day Avg. Volume285,256
30 Day Avg. Volume299,220
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$57.64Price Target Upside74.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-15.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces solvency and refinancing pressure while preserving flexibility to fund research, operations, or strategic initiatives. Although the company remains unprofitable, a low-leverage structure limits fixed financial obligations and provides a more resilient base during continued development.
Improving Free Cash Flow TrendThe smaller latest-TTM free-cash-flow outflow indicates some improvement in cash discipline or spending intensity, which could extend the company’s operating runway. This is not self-funding yet, but continued improvement would reduce the pace of external financing required for pipeline development.
Performance-linked IncentivesTying employee and leadership equity awards to a demanding, multi-year performance condition can strengthen alignment with shareholder outcomes and long-term strategic execution. The forfeiture requirement also limits the value of awards unless management and employees help achieve the specified outcome.
Bears Say
No Revenue And Persistent LossesThe absence of meaningful revenue and continuing large losses show that Faeth has not yet established a commercial earnings engine. This leaves future value dependent on successful clinical and development progress, while ongoing operating costs continue without internally generated revenue support.
Persistent Cash BurnSustained operating and free-cash-flow deficits mean the business is not financing its activities internally. Even with recent improvement, continued development spending and losses may require additional funding, increasing dependence on capital markets and reducing financial flexibility over time.
Potential Shareholder DilutionThe equity program provides financing access but creates a material dilution risk if shares are issued to fund ongoing losses and development. The large preferred-stock conversion already expanded the common share base, potentially reducing existing holders’ ownership percentages and per-share participation.
Faeth Therapeutics News
FTH FAQ
What was Faeth Therapeutics’s price range in the past 12 months?
Faeth Therapeutics lowest stock price was $7.45 and its highest was $42.14 in the past 12 months.
What is Faeth Therapeutics’s market cap?
Faeth Therapeutics’s market cap is $913.98M.
When is Faeth Therapeutics’s upcoming earnings report date?
Faeth Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 53 days.
How were Faeth Therapeutics’s earnings last quarter?
Faeth Therapeutics released its earnings results on Aug 04, 2026. The company reported -$2.84 earnings per share for the quarter, missing the consensus estimate of -$2.636 by -$0.204.
Is Faeth Therapeutics overvalued?
According to Wall Street analysts Faeth Therapeutics’s price is currently Undervalued.
Does Faeth Therapeutics pay dividends?
Faeth Therapeutics does not currently pay dividends.
What is Faeth Therapeutics’s EPS estimate?
Faeth Therapeutics’s EPS estimate is -0.78.
How many shares outstanding does Faeth Therapeutics have?
Faeth Therapeutics has 25,840,425 shares outstanding.
What happened to Faeth Therapeutics’s price movement after its last earnings report?
Faeth Therapeutics reported an EPS of -$2.84 in its last earnings report, missing expectations of -$2.636. Following the earnings report the stock price went down -6.73%.
Which hedge fund is a major shareholder of Faeth Therapeutics?
Currently, no hedge funds are holding shares in FTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Faeth Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.64 (74.81% Upside)
$57.64 (74.81% Upside)
Blogger Sentiment
Bullish
FTH Sentiment 100%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
284.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
495.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Faeth Therapeutics
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
FTH Stock 12 Month Forecast
Average Price Target
$57.64
▲(74.81% Upside)
Technical Analysis
Cellectar Biosciences
―
Cocrystal Pharma
―
BioRestorative Therapies
―
―
Bolt Biotherapeutics
―
Ownership Overview
5.14% Insiders
0.26% Mutual Funds
46.62% Other Institutional Investors
47.92% Public Companies and
Individual Investors